According to Newcastle University, scientists (thanks to the financing of arthritis) have filled a unique approach for biopruding cells that can imitate human tissue-and earn a patent in the USA and Europe. The team under the direction of Professor Kenny Dalgarno has set up a spin-out company, Jetbio, to gain investments in order to introduce the reji printer for use in laboratories around the world.
The process, which is referred to as a reactive beam impingement (reji) bioprinting technology, contains two different liquids together-a one that contained cells that are contained in a networking solution and the other a polymer solution. These mix in the air to form a hydrogel filled with cells that can be printed on almost any surface. The pressure method increases the cell density to about 10 times the other bioprinting technology – with a significantly faster rate. The resulting fabrics are much closer models for human tissue samples.
“The Jetbio team is priority to promote new technologies, the promise to improve both the quality and the speed of drug development. This progress may be able to bring new drugs to the population earlier -and this applies to treatments for arthritis, cancer and cardiovascular diseases. This is a very exciting leap forward, ”said Lucy Donaldson, research director at versus arthritis.
If you bring JetBIOS technology into laboratories to print cells in a 3D matrix that better imitates the human tissue -tests can make tests more precisely and thus revolutionize a long process with high failure rates.
“The discovery of medicinal products is a complicated and extremely expensive process that includes several test rounds before reaching clinical studies. In clinical studies, only each of ten connections tested by connections is carried out to reach the market. These failure rates make it clear that we have to improve our models so that they are more representative for the reaction of the drug in humans. There is currently a great interest in developing better human in -vitro models of diseases and tissues, so that we have better opportunities to test drugs, ”said Professor Dalgarno from the School of Engineering at Newcastle University.
The landscape of drug discovery is changing and interest in new technologies is growing. With the potential that the British start-up uses a rapidly growing global market, the Jetbio team was invited to present ministers and high-ranking public health personalities, including Professor Sir Chris Whitty, Chief Medical Officer for England, in Parliament's houses.
“There was a real sum in our technology and the potential that can stand,” said Professor Dalgarno. “The development of medicinal products is very expensive. So if you can do it more effectively and cheaper, it democratizes the process to a certain extent, since more people could afford the drugs that made it onto the market. “
The printer in coffee machine size also plays a role in regenerative medicine. The treatments for arthritis, which affect 10 million in the UK and more than 500 million people worldwide, are currently limited. Nevertheless, the condition of people hinders the ability to live a full and painless life. For people with arthritis, the goal will be to develop technology to enable quick and tailor -made cell cultivation for use in already available autologous chondrocytes -implantation (ACI). Surgeons can repair cartilage damage by implanting special cells in defects in the cartilage. This technology could improve the accuracy and success of implants.
The printer have the potential to apply to a variety of conditions. An example of the broader use is the re-born, where the Newcastle University team develops an in-vitro model of a cardiac chamber. This combines RJI-Bioprinting with other bioprocessing techniques to create a tissue-controlled “shell” that can be connected to small pumps to imitate the heartbeat. The structure is unique in its structure, contains cardiomyocyte and fibroblast cells that would be present in the heart tissue and is developed to test new approaches to the treatment of heart conditions.